ATE542139T1 - Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit - Google Patents
Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeitInfo
- Publication number
- ATE542139T1 ATE542139T1 AT08800001T AT08800001T ATE542139T1 AT E542139 T1 ATE542139 T1 AT E542139T1 AT 08800001 T AT08800001 T AT 08800001T AT 08800001 T AT08800001 T AT 08800001T AT E542139 T1 ATE542139 T1 AT E542139T1
- Authority
- AT
- Austria
- Prior art keywords
- purinergic
- receptors
- body fluid
- extracellular body
- extracellular
- Prior art date
Links
- 210000001124 body fluid Anatomy 0.000 title abstract 2
- 239000010839 body fluid Substances 0.000 title abstract 2
- 230000001696 purinergic effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007905017A AU2007905017A0 (en) | 2007-09-14 | Purinergic (P2X) receptors in extra-cellular body fluid | |
| PCT/AU2008/001365 WO2009033234A1 (en) | 2007-09-14 | 2008-09-12 | Purinergic (p2x) receptors in extra-cellular body fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE542139T1 true ATE542139T1 (de) | 2012-02-15 |
Family
ID=40451492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08800001T ATE542139T1 (de) | 2007-09-14 | 2008-09-12 | Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8293491B2 (de) |
| EP (1) | EP2201377B1 (de) |
| JP (2) | JP5624885B2 (de) |
| AT (1) | ATE542139T1 (de) |
| AU (1) | AU2008299594B2 (de) |
| NZ (1) | NZ583896A (de) |
| WO (1) | WO2009033234A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2320421T3 (es) | 2001-01-17 | 2009-05-22 | Intreat Pty Limited | Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones. |
| ES2619681T3 (es) | 2007-09-14 | 2017-06-26 | Biosceptre (Aust) Pty Ltd | Novedosos epítopos P2X7 |
| NZ583896A (en) | 2007-09-14 | 2011-05-27 | Biosceptre Int Ltd | Purinergic (p2x) receptors in extra-cellular body fluid |
| ES2610225T3 (es) | 2008-07-04 | 2017-04-26 | Biosceptre (Aust) Pty Ltd | Péptidos y epítopos anti P2X7 |
| WO2011020155A1 (en) | 2009-08-20 | 2011-02-24 | Biosceptre International Limited | Anti p2x7 receptor antibodies and fragments thereof |
| EP3321285B1 (de) | 2009-12-24 | 2019-04-24 | Biosceptre (Aust) Pty Ltd | Antikörper gegen nichtfunktionelle oligomere p2x7-rezeptoren |
| ES2656971T3 (es) | 2010-09-10 | 2018-03-01 | Biosceptre (Aust) Pty Ltd | Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7 |
| BR112013033974A2 (pt) | 2011-07-01 | 2017-02-14 | Biosceptre Int Ltd | terapia de combinação |
| WO2014182601A1 (en) | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
| JP7127021B2 (ja) | 2016-10-21 | 2022-08-29 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 細胞傷害性粒子 |
| CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
| WO2020232313A1 (en) * | 2019-05-14 | 2020-11-19 | Inscent, Inc. | Lateral flow device for target analyte detection using chemosensory proteins |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE920765A1 (en) | 1991-03-12 | 1992-09-23 | Scripps Research Inst | Cell surface receptors homologous to coagulation factors v¹and viii |
| EP0760850A1 (de) | 1994-05-27 | 1997-03-12 | Glaxo Group Limited | P2x REZEPTOREN (PURINOCEPTORENFAMILIE) |
| CA2228999A1 (en) | 1995-08-09 | 1997-02-20 | Institut National De La Sante Et De La Recherche Medicale | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis |
| EP0907729A1 (de) | 1996-04-30 | 1999-04-14 | Smithkline Beecham Plc | Splicevarianten des menschlichen p2x4 rezeptors |
| US6303338B1 (en) | 1996-08-16 | 2001-10-16 | Human Genome Sciences, Inc. | Pancreas-derived plasminogen activator inhibitor |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
| US6133434A (en) * | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| ATE437947T1 (de) | 1998-06-01 | 2009-08-15 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
| DE19829473C2 (de) | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| EP1157038A4 (de) | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | KLONIERUNG EINES P2Y-äHNLICHEN 7TM-REZEPTORS (AXOR17) |
| AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| NL1012452C2 (nl) | 1999-06-28 | 2001-01-02 | Univ Delft Tech | Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten. |
| WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
| AUPR201500A0 (en) | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| ES2320421T3 (es) | 2001-01-17 | 2009-05-22 | Intreat Pty Limited | Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones. |
| JP2003033198A (ja) * | 2001-04-30 | 2003-02-04 | Pfizer Prod Inc | Ｐ２ｘ７受容体活性の調節因子を同定する方法および産物、並びに骨格障害の治療におけるそれらの使用 |
| NZ565994A (en) * | 2001-09-03 | 2010-02-26 | Intreat Pty Ltd | Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
| MXPA05011008A (es) | 2003-04-17 | 2006-03-08 | Affectis Pharmaceuticals Ag | Medios y metodos para diagnosticar y tratar trastornos afectivos. |
| EP1885376A1 (de) | 2005-05-05 | 2008-02-13 | Medicure International Inc. | Hemmung von atp-vermittelten, p2z7-abhängigen leitungsbahnen durch pyridoxal-5-phospast und vitamin b6-verwandte verbindungen |
| US7767789B2 (en) * | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
| WO2007027957A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| WO2008043145A1 (en) * | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Hybridomas producing antibodies against non functional p2x7 receptor |
| WO2008043146A1 (en) | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Antibodies against non functional p2x7 receptor |
| ES2619681T3 (es) | 2007-09-14 | 2017-06-26 | Biosceptre (Aust) Pty Ltd | Novedosos epítopos P2X7 |
| NZ583896A (en) | 2007-09-14 | 2011-05-27 | Biosceptre Int Ltd | Purinergic (p2x) receptors in extra-cellular body fluid |
| ES2610225T3 (es) | 2008-07-04 | 2017-04-26 | Biosceptre (Aust) Pty Ltd | Péptidos y epítopos anti P2X7 |
| WO2011020155A1 (en) | 2009-08-20 | 2011-02-24 | Biosceptre International Limited | Anti p2x7 receptor antibodies and fragments thereof |
| EP3321285B1 (de) | 2009-12-24 | 2019-04-24 | Biosceptre (Aust) Pty Ltd | Antikörper gegen nichtfunktionelle oligomere p2x7-rezeptoren |
| ES2656971T3 (es) | 2010-09-10 | 2018-03-01 | Biosceptre (Aust) Pty Ltd | Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7 |
-
2008
- 2008-09-12 NZ NZ583896A patent/NZ583896A/en unknown
- 2008-09-12 EP EP08800001A patent/EP2201377B1/de active Active
- 2008-09-12 AT AT08800001T patent/ATE542139T1/de active
- 2008-09-12 AU AU2008299594A patent/AU2008299594B2/en active Active
- 2008-09-12 JP JP2010524310A patent/JP5624885B2/ja active Active
- 2008-09-12 US US12/677,795 patent/US8293491B2/en active Active
- 2008-09-12 WO PCT/AU2008/001365 patent/WO2009033234A1/en active Application Filing
-
2012
- 2012-09-25 US US13/626,833 patent/US8658385B2/en active Active
-
2014
- 2014-08-04 JP JP2014158461A patent/JP6008913B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6008913B2 (ja) | 2016-10-19 |
| NZ583896A (en) | 2011-05-27 |
| US20130171666A1 (en) | 2013-07-04 |
| EP2201377B1 (de) | 2012-01-18 |
| US8293491B2 (en) | 2012-10-23 |
| AU2008299594A2 (en) | 2010-04-08 |
| JP5624885B2 (ja) | 2014-11-12 |
| JP2014238416A (ja) | 2014-12-18 |
| WO2009033234A1 (en) | 2009-03-19 |
| EP2201377A1 (de) | 2010-06-30 |
| AU2008299594A1 (en) | 2009-03-19 |
| US8658385B2 (en) | 2014-02-25 |
| US20100248266A1 (en) | 2010-09-30 |
| AU2008299594B2 (en) | 2013-10-03 |
| JP2010539454A (ja) | 2010-12-16 |
| EP2201377A4 (de) | 2010-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE542139T1 (de) | Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit | |
| UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
| CY1119743T1 (el) | Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1 | |
| CU24058B1 (es) | Antagonistas de pcsk9 | |
| NZ718280A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
| UY31114A1 (es) | Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos | |
| CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| BR112014016299A2 (pt) | imunoglobulinas de domínio variável e usos das mesmas | |
| CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
| BRPI0810096A2 (pt) | Anticorpo anti-epcam e seus usos | |
| BR112012012887A2 (pt) | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. | |
| ECSP10010322A (es) | Anticuerpos contra el virus de la influenza y métodos de uso de los mismos | |
| UA106771C2 (uk) | Моноклональні антитіла до прогастрину та їх використання | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| BRPI0816854A2 (pt) | Aparelho regulador de fluido, e, regulador de fluido | |
| MX340724B (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. | |
| AP2010005249A0 (en) | New antibodies specific of the B-amyloid peptides and their uses as diagnostic agents or drugs | |
| IL214779A (en) | Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation | |
| UA99339C2 (ru) | Антитело, которое специфично связывает человеческий tyrp1 | |
| PL1987357T3 (pl) | Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie | |
| BR112014001979A2 (pt) | uso do anticorpo i-3859 para a detecção e diagnóstico de câncer | |
| WO2015009740A3 (en) | Anti-mucin 1 binding agents and uses thereof | |
| EA200970885A1 (ru) | Комбинирование лечения рака с применением il-18 человека и антитела против cd20 | |
| BRPI0814346A2 (pt) | Uso de imidazoquinolinas para o tratamento de doenças dependentes de egfr ou doenças que adquiriram resistência a agentes que são direcionados aos membros da família de egfr. | |
| BR112015027249A2 (pt) | método de diagnóstico de câncer |